With AbbVie’s biopharmaceutical sales retaining a strong growth trajectory, management’s Fiscal 2022 outlook included adjusted diluted EPS estimates in the range of $14 to $14.20, implying growth of 11% at the midpoint compared to Fiscal 2021. As a result of the recent valuation expansion, AbbVie’s yield has declined from just under 5% near December to around 3.1% currently, despite another robust DPS hike during the period. However, considering the strong Fiscal 2022 outlook, I wouldn’t be surprised to see the DPS growth pace returning to double-digits. After all, the current DPS run rate and AbbVie’s adjusted EPS outlook indicate a healthy payout ratio of 40%.

Find out why you and your family should Choose BlueSM for your Medicaid coverage. TipRanks is a comprehensive investing tool that allows private investors and day traders to see the measured performance of anyone who provides financial advice. Turning to Wall Street, AbbVie has a Moderate Buy consensus rating based on 11 Buys and five Holds assigned in the past three months. At $155.47, the average AbbVie price targetimplies 9.3% downside potential. Back in December, AbbVie was trading at a forward P/E close to 9.2.

Medicare

Today, this multiple has expanded to 12.2, despite AbbVie’s strong Fiscal 2022 guidance. Driven by AbbVie’s profit-maximization catalysts mentioned earlier, adjusted earnings per share came in at $3.31, 13.3% higher compared to the prior-year period. Despite the company retaining all of its underlying qualities, with the stock rallying by close to 30% year-to-date, I believe that much of AbbVie’s “easy” upside has already been realized. Another way to prevent getting this page in the future is to use Privacy Pass. You may need to download version 2.0 now from the Chrome Web Store.

Fused with its dividend growth track record prior to its spin-off from Abbot Laboratories, AbbVie has “unofficially” hiked its dividend annually for 50 successive years. Despite such an extended track record which would otherwise suggest Abbvie is a very mature business, the company’s five-year dividend per share CAGR currently stands at a remarkable 17.9%. I am particularly keen on AbbVie’s persistent https://xcritical.com/ efforts to maximize profitability backed by its high-margin business model. It’s an easy way to get claims, wellness and savings information. This health plan is for seniors and persons with disabilities who are eligible for both Medicare and Medicaid. The latest DPS hike back in October was by a slightly softer 8.5% to a quarterly rate of $1.41, implying a modest slowdown in dividend growth.

Pharmacy And Prescription Plans

AbbVie’s latest results illustrated the company’s ability to generate robust cash flows and a rich bottom line once again. AbbVie is a diversified research-based biopharmaceutical company operating globally. AbbVie’s comprehensive product portfolio of therapies aims to cure some of the most complex and severe diseases in the world. Our trusted community experts can you give you the one-on-one help you need to shop for health insurance.

• Fused with its dividend growth track record prior to its spin-off from Abbot Laboratories, AbbVie has “unofficially” hiked its dividend annually for 50 successive years.
• Its capital-return track record, including 50 years of consecutive annual dividend hikes whose growth rate continues to be quite strong, is rather remarkable.
• If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices.
• Back in December, AbbVie was trading at a forward P/E close to 9.2.
• This illustrates how robust and diversified AbbVie’s portfolio is, with Allergan’s acquisition once again proven very beneficial and timely.
• Today, this multiple has expanded to 12.2, despite AbbVie’s strong Fiscal 2022 guidance.

Topics include everything from improving your well-being to explaining health coverage. Get up-to-date information about COVID-19, including your coverage for testing, vaccines and treatment. Following the stock’s strong rally year-to-date, AbbVie’s short-to-medium-term upside could be limited. The fact that AbbVie continues to target double-digit EPS growth despite how mature its portfolio has already evolved is nothing short of impressive. If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices. This plan is available to HealthChoice Illinois, Medicaid, enrollees.

Valuation

Revenues came in at $14.9 billion during the quarter, a 7.4% increase year-over-year. Revenue growth was powered by increased sales in several of its abbvie reviews drugs, including Humira, Skyrizi, and Rinvoq. Specifically, each of these three drugs saw its sales increase by 3.5%, 70.5%, and 84.4%, respectively.

In my view, AbbVie checks all the boxes when it comes to growth, moat and competitive advantages, profitability prospects, and growing capital returns. This new site may be offered by a vendor or an independent third party. In addition, some sites may require you to agree to their terms of use and privacy policy. Search articles and watch videos; ask questions and get answers.

Shop For A Plan

It’s best to check your health care options before using the emergency room . Plus, when you visit in-network providers, you may pay less for care. However, following the stock’s valuation expansion over the past several months, current investors are buying into a feebler dividend yield and a less appealing upside potential, in my view. If you have prescription drug coverage through Blue Cross and Blue Shield of Illinois, learning about your drug benefits can help you and your doctor get the most from your prescription drug coverage. This illustrates how robust and diversified AbbVie’s portfolio is, with Allergan’s acquisition once again proven very beneficial and timely. Hence, the case for double-digit DPS growth over the medium-term remains quite conceivable, in my view.

AbbVie should continue to see its bottom line expanding rapidly over the medium term, driven by a robust sales growth outlook through 2025 and the company’s profit maximization initiatives and catalysts. Again, it’s not a bad yield to grab, considering AbbVie’s dividend growth prospects. However, the overall margin of safety and predictability of future total returns previously offered by the dividend has certainly softened. AbbVie is one of the most reliable and investor-friendly companies in the healthcare sector. Its capital-return track record, including 50 years of consecutive annual dividend hikes whose growth rate continues to be quite strong, is rather remarkable.

What Can I Do To Prevent This In The Future?

If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware.

Having that relationship in place builds a strong base for any care your child needs. Search for doctors, hospitals, dentists, pharmacies and more. Members can log in for the most accurate, personalized search results. If you have a qualifying life event during SEP, you may still be able to enroll in an Individual health plan for you and your family. Indeed, this multiple still appears rather attractive, and I wouldn’t be surprised if a further valuation expansion were to occur. However, with the “easy” money on AbbVie having already been made, I would feel more comfortable booking some profits at this stage.